Management of chronic hepatitis B: Defining the role of lamivudine

Disease Management and Health Outcomes

Volumn 9, Issue 4, 2001, Pages 215-234

  Jarvis, B ^a   Perry, C M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PLACEBO;

CHRONIC HEPATITIS; COUGHING; DISEASE COURSE; DRUG COST; DRUG EFFECT; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEPATITIS B; HUMAN; INSOMNIA; LIVER HISTOLOGY; REVIEW; SEROCONVERSION;

EID: 0035055830     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200109040-00004     Document Type: Review

References (163)

1. Lamivudine: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection
2. Management of HIV infection: The potential role of the lamivudine/zidovudine combination formulation
3. Lamivudine: A review of its therapeutic potential in chronic hepatitis B
4. Nucleoside analogues in the treatment of chronic hepatitis B
5. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men
6. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee
7. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
8. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation
9. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
10. Good results of lamivudine in hepatitis B surface antigen-positive patients with active viral replication before liver transplantation
11. Lamivudine prophylaxis in liver transplantation for hepatitis B in Asians
12. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation
13. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation
14. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin
15. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin
16. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy
17. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: A concise review
18. Hepatitis B virus infection
19. The epidemiology of viral hepatitis in the United States
20. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma
21. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection
22. Natural history of chronic hepatitis B and C
23. Natural history of the HBsAg carrier
24. Natural history of chronic hepatitis B virus infection
25. Delayed clearance of serum HBsAg in compensated cirrhosis B: Relation to interferon alpha therapy and disease prognosis
26. The long-term course of chronic hepatitis B
27. No significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection
28. Natural history and prognostic factors for chronic hepatitis type B
29. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study
30. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver
31. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B
32. Hepatitis B virus the major etiology of hepatocellular carcinoma
33. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma
34. Rising incidence of hepatocellular carcinoma in the United States
35. Prevention of primary liver cancer by immunization
36. Age at first establishment of chronic hepatitis B virus infection and hepatocellular carcinoma risk: A birth order study
37. The increasing incidence of hepatocellular carcinoma
38. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection
39. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States
40. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: A 16-year population-based study
41. More than third of world's population has been infected with hepatitis B virus
42. Epidemiology of hepatitis B and C in Europe
43. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board
44. Hepatitis B and hepatitis delta virus infection in South America
45. Epidemiology and control of hepatitis B infection: A perspective from the Philippines, Asia
46. Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China
47. Progress towards the comprehensive control of hepatitis B in Africa: A view from South Africa
48. Hepatitis B in the Middle East: Aspects of epidemiology and liver disease after infection
49. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia
50. Hepatitis B virus infection in Singapore
51. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: A view from tropical and subtropical Africa
52. Hepatitis B virus carrier prevalence in New Zealand: Population estimates using the 1987 police and customs personnel survey
53. Prevalence in North India of hepatitis B carrier state amongst pregnant women
54. Changing epidemiology of hepatitis B infection in Finland
55. Hepatitis B virus infection in immigrants to the southern Brazilian Amazon
56. Overview of epidemiology and disease burden of hepatitis B in the European region
57. Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through 1994
58. Incidence of hepatitis B virus infection in the United States, 1976-1994: Estimates from the National Health and Nutrition Examination Surveys
59. Interferon treatment for chronic hepatitis B or C infection: Costs and effectiveness
60. Cost-effectiveness of interferon-α2b treatment for hepatitis B e antigen-positive chronic hepatitis B
61. Health care costs associated with chronic hepatitis B
62. Direct and indirect cost of hepatitis B in Korea
63. Cost-effectiveness of lamivudine for the treatment of chronic hepatitis B in Canada
64. An economic evaluation of lamivudine for the treatment of chronic hepatitis B infection in China
65. Cost-effectiveness of one-year treatment with lamivudine (Zeffix) or a single course of A-interferon in chronic hepatitis B
66. Prevention Update recommendations to prevent hepatitis B, From the Centers for Disease Control, virus transmission United States
67. Update on diagnosis, management, and prevention of hepatitis B virus infection
68. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region
69. Vaccines to prevent viral hepatitis
70. Infant and adolescent hepatitis B immunization up to 1999: A global overview
71. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan
72. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
73. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls
74. The treatment of chronic viral hepatitis
75. Hepatitis C, interferon alfa, and depression
76. Interferon monotherapy in chronic hepatitis B
77. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon
78. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B
79. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B
80. Hepatitis B therapy: The plot thickens
81. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
82. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials
83. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B
84. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis
85. Long-term remission of chronic hepatitis B after alpha-interferon therapy
86. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
87. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa
88. Histological improvement after anti-viral treatment for chronic hepatitis B virus infection
89. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B
90. Interferon therapy for the anti-HBe positive form of chronic hepatitis B
91. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B
92. Clinical relevance of hepatitis B viral mutations
93. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen
94. Low-dose recombinant interferon therapy in anti-HBe-positive chronic hepatitis B in Asian Indians
95. A one-year trial of lamivudine for chronic hepatitis B
96. Lamivudine as initial treatment for chronic hepatitis B in the United States
97. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
98. Clinical pharmacokinetics of lamivudine
99. Natural history and lamivudine response in Asians versus Westerners with chronic hepatitis B
100. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy
101. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
102. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection
103. Continued histological improvement in Chinese patients with chronic hepatitis B with 2 years lamivudine
104. Improvements in liver histology and cirrhosis with extended lamivudine therapy
105. Extended lamivudine treatment in patients with HBeAg negative/HBVDNA positive chronic hepatitis B (CHB)
106. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
107. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
108. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B
109. Three year lamivudine therapy in chronic HBV
110. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years
111. Durability of HBeAG seroconversion after lamivudine monotherapy in controlled phase II and III trials
112. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
113. Durable HBeAg response in Chinese patients treated with lamivudine
114. Long-term effect of lamivudine treatment in patients with chronic hepatitis B: Efficacy and durability of response after cessation of treatment
115. Durability of HBeAG responses to lamivudine and interferon in the early post-treatment period in adults with chronic hepatitis B
116. Durable HBeAg and HBsAg seroconversions after lamivudine for chronic hepatitis B (CHB)
117. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea
118. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
119. Enhanced HBEAG Seroconversion rates in Chinese patients on lamivudine
120. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B
121. Short-term corticosteroid therapy in combination with lamivudine: A case of déjà vu?
122. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
123. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection
124. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis
125. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine
126. Lamivudine reduces the need for liver transplantation and improves survival in patients with severely decompensated cirrhosis due to active hepatitis B infection: A controlled study
127. Long-term lamivudine therapy improves Child-Pugh score in patients with hepatitis B-related cirrhosis
128. Lamivudine treatment for decompensated cirrhosis due to hepatitis B: A multicenter longitudinal study
129. Lamivudine improves the Child-Pugh score in HbsAg positive patients listed for transplantation: A single center experience
130. Lamivudine therapy of decompensated chronic hepatitis B
131. Lamivudine treatment of chronic hepatitis B liver transplant candidates: A multi-centre, prospective US study
132. Outcome of treatment with lamivudine for chronic hepatitis B in a compassionate care program in Asia
133. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B
134. Efficacy and safety of lamivudine therapy in patients with decompensated liver cirrhosis caused by HBV infection
135. Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: For whom and when?
136. Is lamivudine beneficial in HBsAG+ patients awaiting liver transplantation? Experience in 182 North American patients
137. Determinants of survival in 133 patients with decompensated chronic hepatitis B treated with lamivudine
138. Prediction of long-term response to lamivudine by measuring HBV-DNA levels at month 3 in patients with chronic hepatitis B
139. Long-term therapy of chronic hepatitis B with lamivudine
140. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance
141. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
142. Enhanced HBeAg and ALT responses during long term lamivudine treatment in Chinese patients
143. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy
144. Lamivudine therapy for chronic hepatitis B: Is longer duration of treatment better?
145. Combination chemotherapy for hepatitis B virus: The final solution?
146. Combination chemotherapy for hepatitis B virus: The path forward?
147. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy
148. The cost-effectiveness of the introduction of lamivudine for the treatment of chronic hepatitis B in Australia
149. The potential impact of lamivudine (100 mg) on the clinical management of chronic hepatitis B in Australia
150. A drug budget perspective of lamivudine compared with interferon-α in the treatment of precore chronic hepatitis B in Italy
151. Cost comparison of interferon and lamivudine for the treatment of chronic hepatitis B
152. A drug budget perspective of lamivudine compared with interferon-α in the treatment of chronic hepatitis B in the United States
153. The long-term cost-effectiveness of lamivudine for the treatment of chronic hepatitis B in the United States
154. The short-term cost-effectiveness of lamivudine for the treatment of chronic hepatitis B in the United States
155. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: A viral dynamics study
156. A pilot study with lamivudine and famciclovir for the treatment of chronic hepatitis B
157. Combination treatment with lamivudine plus interleukin-12 shows greater antiviral activity in chronic hepatitis B
158. A study on the short-term efficacy of thymosin α1 (Tα1) combined with lamivudine in treating patients with chronic hepatitis B
159. Immunosuppression and reactivation of hepatitis B in the lamivudine era: Opportunities for prevention and exploitation?
160. Chronic hepatitis B: New therapies on the horizon?
161. Clinical potential of emerging new agents in hepatitis B